Stock Digest

Wednesday, 24 May, 2023



Nova Wellness Group Bhd

Declined sales order and increased expenses dragged margin

Summary

- Nova Wellness Group Bhd's (NOVA) 3Q23 core net profit tumbled 39.8% YoY to RM2.9m, bringing 9M23 core net profit to RM10.9m (-24.9% YoY). The results came in below expectations, amounting to 62.6% of our full year forecast of RM17.4m and 60.6% of the consensus forecast of RM18.0m. Key deviation was mainly attributed to a lower-than-expected contribution from the House Brand segment.
- YoY, core net profit fell 39.8% YoY to RM2.9m, primarily resulted from (i) a decrease
 in revenue from House Brand segment as compared to the higher revenue from the
 OEM segment, and (ii) higher cost of sales, admin costs (employee bonus and
 benefits) and other operating expenses (higher R&D costs) despite the decrease in
 selling and distribution expenses due to lower salesman commission expenses in
 tandem with the decline in revenue. Overall, core net profit margin shrank from
 40.7% to 26.6% YoY.
- QoQ, core net profit plummeted 20.1%, resulted primarily from the (i) decrease in sales order for the House Brand products, and (ii) increase in admin and operating expenses.
- The House Brand segment continued to be the primary source of revenue, accounting for 86.1% of the total revenue in the current quarter, with the OEM revenue contributing the remaining 13.9%. The revenue from OEM witnessed an increase of 275.2% YoY and 150.8% QoQ, as the group focused more on selling OEM products in view of the lower demand in the House Brand segment.
- Production facilities wise, the ongoing construction of Phase 2 of NOVA's new plant
 is underway. The upcoming factory will serve as an expansion of its current
 supplement and skin care manufacturing. As for the skincare manufacturing, it will
 introduce a fresh lineup of products including cream, balms, ointment, and
 shampoos. Since this will involve a new product range and brand, it is expected to
 take approximately 2-3 years for it to establish a strong presence in the market.
- Moving forward, we expect a slower growth on NOVA's performance as the group navigates the post-Covid-19 landscape and global economic uncertainties. Nonetheless, NOVA remains committed to expand its product portfolio and market presence while striving for enhanced production efficiencies. Additionally, the group is working on introducing new programmes for its partners.

Quarterly performance								
FYE Jun (RM m)	3QFY22	2QFY23	3QFY23	QoQ (%)	YoY (%)	9MFY22	9MFY23	YoY (%)
Revenue	12.0	12.0	11.0	(8.0)	(8.0)	38.6	35.1	(9.1)
EBITDA	6.0	5.4	4.2	(21.2)	(29.0)	19.2	15.3	(20.0)
PBT	5.6	5.1	3.9	(22.9)	(31.1)	18.4	14.6	(20.6)
PAT	4.9	3.7	2.9	(20.1)	(39.8)	14.5	10.9	(24.9)
Core PATMI	4.9	3.7	2.9	(20.1)	(39.8)	14.5	10.9	(24.9)
Reported PATMI	4.9	4.3	2.9	(31.4)	(39.8)	14.5	11.5	(20.7)
Core EPS (sen)	1.5	1.3	0.9	(31.4)	(39.8)	4.5	3.6	(20.7)
EBITDA margin (%)	49.7	44.8	38.3			49.7	43.7	
PBT margin (%)	47.1	42.1	35.3			47.7	41.6	
Core PATMI margin (%)	40.7	30.6	26.6			37.6	31.1	

Results Note - 3QFY23

Ng Hui Yee hyng@msec.com.my (603) 2201 2100

SELL	
Share price	RM0.86
Target price	RM0.73
Previous TP	RM0.75
Capital upside	-15.1%
Dividend return	1.8%
Total return	-13.3%

Company profile Principally involved in the development, production and sales of nutraceutical and skincare products.

Stock information 0201 Bursa Code Bloombera ticker **NOVA MK** Listing market MAIN Share issued (m) 318.7 Market Cap (m) 274.1 0.957 / 52W High/Low 0.814 Est. Free float 140 0.5 3-mth avg vol ('000) 39.3 Shariah compliant Yes

Major shareholders	%
Tan Sok Mooi	42.4
Phang Nyie Lin	7.9
Phang Yeen Nung	7.9

Share price vs. KLCI (%)								
Hist. return	1M	3M	12M					
Absolute	-1.1	-3.2	-4.1					
Relative	-0.4	0.0	4.0					

Earnings snapshot									
FYE (Dec)	FY22	FY23f	FY24f						
PATMI (m)	16.1	14.8	16.6						
EPS (sen)	5.1	4.6	5.2						
P/E (x)	17.0	18.5	16.5						



Stock Digest

Wednesday, 24 May, 2023



Valuation & Recommendation

- As the reported earnings came in below our expectations, we slashed the earnings forecast by 12.9%, 11.2%, and 15.2% to RM14.8m, RM16.6m, and RM17.8m for FY23f, FY24f, and FY25f respectively. The forecasted earnings take into account the slower than expected growth on the contribution from House Brand segment, as well as the higher contribution from OEM segment.
- We remained our SELL recommendation on NOVA, with a revised target price of RM0.73 (previous TP: RM0.75) as we rolled over to FY24f forecasted earnings. The target price is derived by ascribing a P/E of 14.0x to FY24f EPS of 5.2 sen. Meanwhile, NOVA remained committed to deliver its dividend policy of distributing not less than 30.0% of its annual net profit after tax.
- Risks to our recommendation include the possibility of supply chain disruptions, both domestically and internationally, which may impact the availability of raw materials. Besides, the group is exposed to foreign currency risk relating to USD as a significant portion of its raw material purchases from abroad are denominated in USD. Any depreciation in ringgit against USD will result in increased costs for raw materials and packaging materials, potentially affecting the group's margin.

Financial Highlights

All items in (RM m) unless otherwise stated

Income Statement						Balance Sheet					
FYE Jun (RM m)	FY21	FY22	FY23f	FY24f	FY25f	FYE Jun (RM m)	FY21	FY22	FY23f	FY24f	FY25f
Revenue	40.5	49.1	47.1	49.7	52.3	Cash	27.7	20.4	30.4	37.6	43.6
EBITDA	19.8	21.3	20.5	23.1	24.8	Receivables	15.2	17.9	16.1	16.3	17.2
EBIT	18.7	19.8	19.2	21.6	23.2	Inventories	14.5	19.7	15.5	13.8	14.2
Net finance income/ (cost)	0.6	0.4	0.5	0.5	0.5	PPE	33.8	41.7	47.8	53.8	59.6
Associates & JV	-	-	-	-	-	Others	13.3	12.7	13.4	14.2	15.0
Profit before tax	19.3	20.3	19.7	22.1	23.7	Assets	104.5	112.4	123.2	135.7	149.7
Tax	(4.7)	(4.2)	(4.9)	(5.5)	(5.9)						
Net profit	14.6	16.1	14.8	16.6	17.8	Debts	-	-		-	-
Minority interest	-	-	-	-	-	Payables	3.2	5.9	5.2	5.0	5.1
Core earnings	14.6	16.1	14.8	16.6	17.8	Others	7.3	6.0	7.7	8.9	10.2
Exceptional items	(0.0)	-	-	-	-	Liabilities	10.5	11.9	13.0	13.8	15.3
Reported earnings	14.6	16.1	14.8	16.6	17.8						
						Shareholder's equity	93.9	100.5	110.2	121.9	134.3
						Minority interest	-	-	-	-	-
Cash Flow Statement						Equity	93.9	100.5	110.2	121.9	134.3
FYE Jun (RM m)	FY21	FY22	FY23f	FY24f	FY25f						
Profit before taxation	19.3	20.3	19.7	22.1	23.7	Valuation & Ratios					
Depreciation & amortisation	1.1	1.4	1.3	1.5	1.7	FYE Jun (RM m)	FY21	FY22	FY23f	FY24f	FY25f
Changes in working capital	(6.7)	(5.2)	5.3	1.2	(1.2)	Core EPS (sen)	4.6	5.1	4.6	5.2	5.6
Share of JV profits	=	-	-	-	-	Diluted EPS (sen)	4.6	5.1	4.6	5.2	5.6
Taxation	(4.7)	(4.2)	(4.9)	(5.5)	(5.9)	P/E (x)	18.8	17.0	18.5	16.5	15.4
Others	0.1	(0.1)	1.4	1.2	1.4	DPS (sen)	3.0	3.2	1.4	1.6	1.7
Operating cash flow	9.1	12.3	22.8	20.5	19.7	Dividend yield	3.5%	3.7%	1.6%	1.8%	1.9%
						BVPS (RM)	0.29	0.32	0.35	0.38	0.42
Net capex	(0.9)	(13.5)	(8.1)	(8.8)	(6.4)	P/B (x)	2.9	2.7	2.5	2.2	2.0
Others	(0.3)	-	-	-	-						
Investing cash flow	(5.8)	(9.5)	(8.3)	(8.3)	(8.3)	EBITDA margin	48.9%	43.3%	43.5%	46.5%	47.5%
						EBIT margin	46.2%	40.4%	40.7%	43.5%	44.3%
Changes in borrowings	=	-	-	-	-	PBT margin	47.6%	41.3%	41.9%	44.6%	45.3%
ssuance of shares	=	0.0	-	-	-	PAT margin	36.0%	32.8%	31.4%	33.4%	34.0%
Dividends paid	(9.5)	(10.2)	(4.4)	(5.0)	(5.3)	Core PAT margin	36.0%	32.8%	31.4%	33.4%	34.0%
Others	1.0	-	-	-	-						
Financing cash flow	(8.5)	(10.1)	(4.4)	(5.0)	(5.3)	ROE	16.1%	16.6%	14.0%	14.3%	13.9%
						ROA	14.5%	14.9%	12.5%	12.8%	12.5%
Net cash flow	(5.2)	(7.3)	10.0	7.2	6.0	Net gearing	CASH	CASH	CASH	CASH	CASH
Forex	-	-	-	-	-						
Others	0.0	-	-	-	-						
Beginning cash	32.9	27.7	20.4	30.4	37.6						
Ending cash	27.7	20.4	30.4	37.6	43.6						

Disclaimer: This report has been prepared by Malacca Securities Sdn Bhd (MSSB) pursuant to the Research Incentive Program under Bursa Research Incentive Scheme ("Bursa RISE") administered by Bursa Malaysia Berhad. This report has been produced independent of any influence from Bursa Malaysia Berhad or the subject company. Bursa Malaysia Berhad and its group of companies disclaims any and all liability, howsoever arising, out of or in relation to the administration of Bursa Research Incentive Program and/or this report. MSSB and/or its associated persons does not warrant, represent and/or guarantee the accuracy of any opinions and information herein in any manner whatsoever and no reliance upon the report and/or any parts thereof by anyone shall give rise to any claim whatsoever against MSSB.